Per user reports across athlete and biohacker communities:

• Onset (acute mechanism): No subjective effect at 1 hr post-dose; the Shaw mechanism is biochemical, not perceptible. Some users notice mild fullness/satiety from the protein load.
• Glycine load (15-20 g): ~5 g glycine produces mild subjective warmth or relaxation in some users 30-60 min post-dose; same pattern as standalone glycine. Most users feel nothing acutely.
• Pre-training (Shaw protocol): No perceptible performance change in-session. The intervention is a substrate-loading bet on cumulative tendon health, not an acute performance enhancer.
• Tendon/joint subjective changes: 2-4 weeks for early signal in mild tendinopathy; 8-12 weeks for stable change. "Stiffness on first reps of training" or "joint clicking" may reduce; full pain elimination uncommon at supplement doses.
• Skin/hair: 4-8 weeks for subjective changes. Skin elasticity / hydration / fewer fine lines are the most-reported aesthetic benefits. Hair / nail growth claims are weaker.
• Sleep (pre-bed dose): 30-50% of glycine-responders report subjectively easier sleep onset at 15-20 g pre-bed; same pattern as standalone glycine 3 g (with which gelatin overlaps amino-acid-wise).
• Morning: No grogginess. No tolerance, no rebound.
• GI: Some users report mild bloating or constipation at higher doses (20+ g). Switching from gelatin (higher MW) to hydrolysate (lower MW) often resolves.

Variability is moderate. The acute mechanism (Shaw 2017) is biochemical, so subjective variability is mostly orthogonal to the actual effect. The aesthetic and joint-comfort indications have higher placebo-component variability.

• Tolerance buildup: None established. Substrate-level supplementation; no receptor desensitization.
• Recommended cycle: None needed. Daily-safe indefinitely.
• Reset protocol: N/A.

Synergistic with

• Vitamin C — required cofactor; not optional in the Shaw protocol. 50-100 mg co-administered.
• BPC-157 — substrate (gelatin) + cell-migration / angiogenesis (BPC-157). Convergent tendon repair. Common in athlete recovery stacks.
• TB-500 — same logic as BPC-157; substrate + cell migration.
• Vitamin D3 + K2 + calcium — bone matrix synergy. Collagen is the organic scaffold; D3+K2+Ca builds the mineral phase.
• Whey / casein protein — complementary amino acid profile. Whey for muscle protein synthesis (leucine-driven mTOR), gelatin for connective tissue (glycine + hydroxyproline substrate). They cover different anabolic targets.
• Heavy slow resistance / eccentric loading — the Shaw mechanism requires mechanical loading; gelatin without loading is just protein.
• Caffeine — common pre-training stack; no documented antagonism.
• Creatine — independent pathways; no interaction.

Replaces (partially)

• Standalone glycine 3 g pre-bed — 15 g gelatin contributes ~5 g glycine, exceeding the standalone dose. If the user takes pre-bed gelatin, separate glycine is partial duplication.
• Bone broth — gelatin powder is cheaper, more concentrated, easier to dose, and matches RCT protocols. Bone broth is a whole-food alternative with the same active components but less consistent dosing.

Avoid stacking with

• No clinically meaningful contraindications. Gelatin is one of the safest supplements in the pharmacopeia.

Neutral / safe co-administration

• All canonical V4/V5 stack components.
• All Rx medications — no documented interactions.
• All other amino acids, minerals, vitamins.

Gelatin is one of the lowest-interaction supplements in the pharmacopeia.

Limited PGx data of practical significance for gelatin:

• GLYCINE-SHMT pathway variants (SHMT1, SHMT2) — affect glycine ↔ serine interconversion. Not actionable for gelatin dose; the supplemental dose dwarfs metabolic flux variability.
• Vitamin C transporter / metabolism (SLC23A1, SLC23A2) variants — affect ascorbate uptake and tissue saturation. Could theoretically alter the vitamin C cofactor adequacy in the Shaw protocol, but the 50-100 mg dose is well above scurvy threshold and likely saturating. Worth filing for context.
• COL1A1 / COL1A2 variants — collagen type I gene polymorphisms associated with bone density, tendon injury risk, etc. Don't translate to actionable gelatin-dose recommendations but explain inter-individual variation in tendon resilience baseline.
• MMP variants (matrix metalloproteinase) — affect collagen turnover. Background variable, not actionable.
• 23andMe relevance for the user (June 2026 results): worth noting any COL1A1/COL1A2 / MMP variants for tendon-injury-risk context. No actionable change to gelatin dose is expected based on current PGx evidence. File for context.

Recommended for the user: Great Lakes Wellness Collagen Hydrolysate or Bulk Supplements Collagen Peptides for daily 15 g pre-training dose. Cold-water-mix in OJ (covers vitamin C cofactor) or in water with 50-100 mg ascorbic acid. Cost: ~$15-30/mo. Pair with existing V4 vitamin C if separate.

Baseline (before starting)

• Joint comfort log — daily 1-10 scale on knees, elbows, shoulders (or sport-specific load points). Most actionable subjective measure.
• Training durability log — sessions completed, sessions missed/modified due to joint or tendon discomfort. The most relevant outcome measure for the user.
• VISA-P / VISA-A / VISA-G questionnaires — if active tendinopathy at patellar, Achilles, or gluteal regions. Validated tendon pain questionnaires.
• hsCRP — baseline systemic inflammation; useful as confound check.
• Vitamin D, calcium, magnesium status — bone matrix cofactors; the user likely has these from V4.
• Tendon imaging (US or MRI) — if affordable / clinically warranted; cross-sectional area baseline.

During use

• Joint comfort log weekly.
• Training durability log session-by-session.
• VISA-P/A questionnaire monthly if tendinopathy active.
• Skin elasticity (if aesthetic indication) — weeks 8, 12 subjective rating.

Post-cycle (if ever cycled)

• N/A — no cycling needed.

Trial framework (recommended for the user)

Run as a 12-week structured trial:

1. Baseline log of training durability + joint comfort × 2 weeks.
2. Add 15 g gelatin + 50 mg vitamin C, 1 hr pre-training, on all training days × 12 weeks.
3. Compare training durability + joint comfort + injury frequency vs baseline.
4. Decision rule: if subjective tendon resilience improves and training load tolerated, continue indefinitely. If no perceptible change at 12 weeks despite compliance, drop or reduce to maintenance 10 g/day.